Finally, our kinetics study revealed, for the first time to our knowledge, that by sequestering and consuming IL-2, intratumoral Tregs hindered CD8+ TIL hyperactivation in the early phase of tumor growth and promoted TOX-dependent CD8+ TIL exhaustion during tumor progression. The gene discussed is IL2; the disease is neoplasm.